Epigenomics' Colorectal Cancer Test Approved in Argentina | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics and VSA Alta Complejidad today announced that VSA has been approved to market Epigenomics' Epi proColon kit in Argentina.

The companies have worked together since last year to secure regulatory approval for Epigenomics' blood-based colorectal cancer test from ANMAT, which regulates diagnostic tests in Argentina. They also said that VSA has forged relationships with leading diagnostic reference laboratories in Argentina to make Epi proColon available there.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.